|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||71.05 - 72.14|
|52 Week Range||60.53 - 76.51|
|PE Ratio (TTM)||43.87|
|Earnings Date||Nov 1, 2018|
|Forward Dividend & Yield||0.76 (1.05%)|
|1y Target Est||79.62|
In 2012, Baxter International (BAX) adopted a $2 billion share buyback program. In November 2016 and February 2018, the company increased the program by $1.5 billion each.
Sales from Baxter International’s (BAX) advanced surgery business, which includes biological products and medical devices that are used in surgical procedures, increased from $178 million in the second quarter of 2017 to $204 million in the second quarter of 2018. The marketing and administrative expenses incurred by Baxter International increased from $630 million in the second quarter of 2017 to $681 million in the second quarter of 2018.
Baxter International’s (BAX) global business units include renal care, medication delivery, pharmaceuticals, nutrition, advanced surgery, acute therapies, and other, which primarily includes sales from Baxter’s pharmaceutical partnering business. Baxter International generated revenue of $2.84 billion in the second quarter compared to $2.6 billion in the comparable period in 2017. Baxter International incurred a cost of sales of $1.6 billion in the second quarter compared to $1.47 billion in the second quarter of 2017.
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington ...
(Reuters) - British engineering firm Smiths Group Plc (SMIN.L) is close to abandoning talks with U.S.-based ICU Medical Inc (ICUI.O) over a 7 billion pound ($9 billion) merger of their healthcare divisions, ...
British engineering firm Smiths Group Plc is close to abandoning talks with U.S.-based ICU Medical Inc over a 7 billion pound ($9 billion) merger of their healthcare divisions, Sky News reported on Monday. Smiths is leaning toward a decision to halt negotiations with ICU Medical about the tie-up, more than two months after they got under way, Sky News said. A final decision has yet to be made by Smiths and any change in its position would be announced immediately to the London Stock Exchange, Sky News reported, citing a person close to the British company.
TransEnterix (TRXC) reported its second-quarter earnings on Tuesday, August 7, before the market opened. TransEnterix generated second-quarter revenues of $6.4 million compared to $1.6 million in the second quarter of 2017.
On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.
In the second quarter of 2018, Zimmer Biomet’s (ZBH) Knees segment generated revenues $703.0 million, reflecting ~3.4% year-over-year growth. In Q2 2018, in the Americas, EMEA (Europe, Middle East, and Africa), and Asia-Pacific regions, Zimmer Biomet’s Knees segment generated revenues of $408.0 million, $171.0 million, and $124.0 million, respectively, reflecting ~0.7%, ~7.0%, and ~8.1% YoY growth. In the first half of 2018, Zimmer Biomet’s Knees segment generated revenues of $1.4 billion, reflecting ~2.6% YoY growth.
In the second quarter, Zimmer Biomet (ZBH) generated revenues of $2.0 billion compared to $1.9 billion in the second quarter of 2017, a ~3% YoY increase. In the first half of 2018, Zimmer Biomet reported net revenues of $4.0 billion compared to $3.9 billion in the first half of 2017.
Baxter International Inc. (BAX), a leader in innovative technology for medication delivery, today announced the CE marking of the Evo IQ Infusion System. In addition to the planned marketing of the device in the United Kingdom, Ireland and New Zealand, the Evo IQ Infusion System recently received regulatory approval by the Therapeutic Goods Administration (TGA) in Australia.
Is there more downside risk just ahead or should be look at this weakness as an opportunity to do some buying? In the updated daily bar chart of BAX, below, we can see that prices made a small gap to the downside with heavy volume. The daily On-Balance-Volume (OBV) was steady ahead of this recent dip so we don't have a signal that sellers had become more aggressive in advance of the decline.
Baxter International (BAX) released its Q2 2018 results on July 26. During the quarter, Baxter expanded its medication delivery portfolio with two new infusion pumps. Baxter International’s marketing and administrative expenses increased 8% from $630 million in Q2 2017 to $681 million in Q2 2018, and its research and development expenses increased by 12% from $155 million in Q2 2017 to $174 million in Q2 2018.
NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $440 million.
Baxter (BAX) delivered earnings and revenue surprises of 8.45% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Deerfield, Illinois-based company said it had profit of 63 cents per share. Earnings, adjusted for non-recurring costs, came to 77 cents per share. The results beat Wall Street expectations. The average ...